Nicholas Fidelman


Director, Interventional Oncology, San Francisco
Interventional radiologist

Dr. Nicholas Fidelman is a radiologist who specializes in caring for patients with liver cancer, metastatic colorectal cancer and neuroendocrine tumors. He has expertise in liver-directed therapy, a treatment that directly targets cancer in the liver. He also is experienced in treating portal hypertension (high blood pressure in the veins connecting the digestive organs to the liver), biliary disorders (which affect the bile ducts and gallbladder), urinary system disorders, and in performing dialysis interventions (minimally invasive procedures to restore blood flow in vessels used for dialysis).

Fidelman's research focuses on clinical trials investigating novel treatments for liver cancer, outcomes of commonly performed procedures in interventional radiology, and on improving the safety and efficacy of image-guided treatments.

Fidelman earned his medical degree from UCSF, where he also completed a residency in radiology and a fellowship in vascular and interventional radiology.

  • Education

    UCSF School of Medicine, 2002

  • Residencies

    UCSF, Radiology, 2007

  • Fellowships

    UCSF, Vascular and Inteventional Radiology, 2008

  • Academic Title


  • Languages


Clinics I work with

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

Gastrointestinal Surgical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

Interventional Radiology Clinic

505 Parnassus Ave., Room M-361
San Francisco, CA 94143

Liver Tumor Clinic

350 Parnassus Ave., Suite 300
San Francisco, CA 94117

Pancreas Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

Radiology at Mission Bay

1975 Fourth St., First Floor, C1422
San Francisco, CA 94158

Decorative Caduceus

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Hepatic progression-free interval (H-PFS)


Decorative Caduceus

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine T...

The point estimate and 95% confidence interval of overall response rate will be obtained for each of the three liver-directed therapy groups (cryoablation, transarterial embolization(TAE) , radioembolization (RE)) separately. The ...